NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis

• Status: Completed
• Trial end date: 2005-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to decide if controlling stomach acid is related to healing of erosive esophagitis after treatment with esomeprazole magnesium (NEXIUM®) 10 mg and 40 mg once daily.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Esomeprazole

Criteria

Inclusion Criteria:

• Male or non-pregnant, non-lactating female patients between the ages of 18 and 75 years

• Patients must have moderate to severe erosive esophagitis

Exclusion Criteria:

• Significant gastrointestinal bleeding

• Severe heart, lung, liver or kidney disease

• Esophagitis not related to acid reflux